Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

This study tests whether sargramostim (GM-CSF), a drug that stimulates the immune system and is already approved for other uses, can slow or improve symptoms of Alzheimer's disease in older adults with mild to moderate dementia. **You may be eligible if...** - You are between 60 and 85 years old - You have been diagnosed with mild or moderate Alzheimer's disease - You have a brain scan or blood test showing signs of amyloid protein buildup consistent with Alzheimer's - You have a dedicated caregiver who spends at least 12 hours per week with you and can attend visits - You scored between 4 and 24 on a standard memory test (MoCA) **You may NOT be eligible if...** - Your dementia is severe - You do not have a caregiver who can accompany you - You are unable to provide consent or assent - You live too far from the study site - You have serious health conditions that would prevent safe participation Talk to your doctor to see if this trial is right for you.